埃索美拉唑联合左氧氟沙星、奥硝唑治疗Hp阳性慢性胃炎的疗效

Esomeprazole Combined with Levofloxacin and Ornidazole for Helicobacter Pylori-Positive Chronic Gastritis

目的探讨埃索美拉唑联合左氧氟沙星、奥硝唑治疗Hp阳性慢性胃炎的临床疗效。方法将80例Hp阳性的慢性胃炎患者按入院的先后顺序分为观察组和对照组,每组40例。观察组采用埃索美拉唑镁肠溶片联合奥硝唑胶囊分散片、左氧氟沙星片治疗。对照组采用埃索美拉唑镁肠溶片联合阿莫西林胶囊、克拉霉素分散片治疗。观察2组Hp根除率、不良反应及临床疗效。结果观察组总有效率为95.0%,明显高于对照组的75.0%(P<0.05)。观察组Hp根除率为85.0%,明显高于对照组的70.0%(P<0.05)。2组均未见不良反应。结论采用埃索美拉唑联合奥硝唑、左氧氟沙星治疗Hp阳性的慢性胃炎疗效确切,Hp根除率高,安全性良好,可作为根除Hp的一个较好的选择。

Objective To explore the clinical efficacy of esomeprazole combined with levofloxacin and ornidazole in the treatment of Helicobacter pylori（Hp）-positive chronic gastritis. Methods According to the order of admission, 80 Hp-positive patients with chronic gastritis were divided into two groups, with 40 patients in each group. The observation group was treated with entericcoated tablets of esomeprazole magnesium, dispersible tablets of ornidazole, and levofloxacin tablets. The control group was treated with enteric-coated tablets of esomeprazole magnesium,amoxicillin capsules, and dispersible tablets of clarithromycin. Hp eradication rate, adverse reactions and curative effect were observed in both groups. Results The total effective rate and Hp eradication rate in observation group （95.0% and 85.0%, respectively） were significantly higher than those in control group（75.0% and 70.0%, respectively）（P〈0.05）. No adverse reactions were found in both groups. Conclusion Combined treatment with esomeprazole, levofloxacin and ornidazole is an effective and safe option and leads to a high Hp eradication rate in Hp-positive patients with chronic gastritis.